Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - atenolol - tablets - atenolol 100 mg - atenolol - atenolol - management of angina pectoris and hypertension,including hypertension of renal origin. late intervention after acute myocardial infarction.

Israel - English - Ministry of Health

abic ltd. - atenolol - tablets - atenolol 50 mg - atenolol - atenolol - management of angina pectoris and hypertension, including hypertension of renal origin. late intervention after acute myocardial infarction

Israel - English - Ministry of Health

teva israel ltd - diltiazem hydrochloride - tablets - diltiazem hydrochloride 30 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - diltiazem hydrochloride - tablets - diltiazem hydrochloride 60 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

Israel - English - Ministry of Health

unipharm ltd, israel - pravastatin sodium - tablets - pravastatin sodium 40 mg - pravastatin - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet other nonpharmacological measures alone have been inadequate. primary prevention of coronary events: in hypercholesterolemic patients wihthout clinically evident coronary heart disease pravastatin is indicated to: 1) reduce the risk of myocardial infarcton. 2) reduce the risk for revascularization. 3) reduce the risk of deaths due to cardiovascular causes with no increase in death due to non-cardiovascular causes. secondary prevention of cardiovascular events: a) atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: 1)slow the progression of coronary atherosclerosis. 2) reduce the risk of acute coronary events. b) myocardial infarction: in patients with previ

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - desogestrel; ethinylestradiol - tablets - desogestrel 150 mcg; ethinylestradiol 20 mcg - desogestrel - desogestrel - oral contraception

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - clomifene citrate - tablets - clomifene citrate 50 mg - clomifene - clomifene - in women : ovulatory failure in patients desiring pregnancy.

Israel - English - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - tablets - terazosin as monohydrachloride dihydrate 5 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.

Israel - English - Ministry of Health

biotis ltd - terazosin as monohydrachloride dihydrate - tablets - terazosin as monohydrachloride dihydrate 10 mg - terazosin - terazosin - for symptomatic treatment of urinary obstruction caused by benign prostatic hypertrophy (bph). for mild to moderate hypertension.

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - finasteride - tablets - finasteride 5 mg - finasteride - finasteride - for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to: reduce the risk of acute urinary retention. reduce the risk of surgery including transurethral resection of the prostate (turp)and prostatectomy. pro-cure causes regression of the enlarged prostate, improves urinary flow and improves the symptoms assocciated with bph. patients with an enlarged prostate are the appropriate candidates for therapy with pro-cure.